{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:46:11Z","timestamp":1789717571823,"version":"4.0.1"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Despite the development of a vaccine against cutaneous leishmaniasis in preclinical and clinical studies, we still do not have a safe and effective vaccine for human use. Given this situation, the search for a new prophylactic alternative to control leishmaniasis should be a global priority. A first-generation vaccine strategy\u2014leishmanization, in which live <jats:italic>Leishmania major<\/jats:italic> parasites are inoculated into the skin to protect against reinfection, is taking advantage of this situation. Live attenuated <jats:italic>Leishmania<\/jats:italic> vaccine candidates are promising alternatives due to their robust protective immune responses. Importantly, they do not cause disease and could provide long-term protection following challenges with a virulent strain. In addition to physical and chemical methods, genetic tools, including the Cre-<jats:italic>loxP<\/jats:italic> system, have enabled the selection of safer null mutant live attenuated <jats:italic>Leishmania<\/jats:italic> parasites obtained by gene disruption. This was followed by the discovery and introduction of CRISPR\/Cas-based gene editing tools, which can be easily and precisely used to modify genes. Here, we briefly review the immunopathology of <jats:italic>L. major<\/jats:italic> parasites and then present the classical methods and their limitations for the production of live attenuated vaccines. We then discuss the potential of current genetic engineering tools to generate live attenuated vaccine strains by targeting key genes involved in <jats:italic>L. major<\/jats:italic> pathogenesis and then discuss their discovery and implications for immune responses to control leishmaniasis.<\/jats:p>","DOI":"10.3389\/fpubh.2024.1382996","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T05:14:11Z","timestamp":1720156451000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["From classical approaches to new developments in genetic engineering of live attenuated vaccine against cutaneous leishmaniasis: potential and immunization"],"prefix":"10.3389","volume":"12","author":[{"given":"Zahra","family":"Rooholamini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Dianat-Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Esmaeilifallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Khanahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00281-020-00788-y","article-title":"Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs","volume":"42","author":"Kaye","year":"2020","journal-title":"Semin Immunopathol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/tropicalmed8090430","article-title":"Systematic review of treatment failure and clinical relapses in leishmaniasis from a multifactorial perspective: clinical aspects, factors associated with the parasite and host","volume":"8","author":"Santos","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/20477724.2022.2133452","article-title":"Prevalence of cutaneous leishmaniasis in the Middle East: a systematic review and meta-analysis","volume":"117","author":"Karami","year":"2022","journal-title":"Pathog Glob Health."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1016\/j.vaccine.2023.01.057","article-title":"Vaccine value profile for leishmaniasis","volume":"41","author":"Kaye","year":"2023","journal-title":"Vaccine."},{"key":"B5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijid.2014.04.023","article-title":"Revisiting leishmaniasis in the time of war: the Syrian conflict and the Lebanese outbreak","volume":"29","author":"Alawieh","year":"2014","journal-title":"Int J Infect Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00704-023-04726-4","article-title":"The potential effects of climate change on the climatic suitability patterns of the Western Asian vectors and parasites of cutaneous leishmaniasis in the mid- and late twenty-first century","volume":"155","author":"Tr\u00e1jer","year":"2024","journal-title":"Theor Appl Climatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7555\/JBR.27.20120064","article-title":"Development of leishmania vaccines: predicting the future from past and present experience","volume":"27","author":"Mutiso","year":"2013","journal-title":"J Biomed Res."},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.75000","article-title":"Vaccines for human leishmaniasis: where do we stand and what is still missing?","volume-title":"Leishmaniases as Re-emerging Diseases.","author":"Cec\u00edlio","year":"2018"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1080\/14760584.2021.1969231","article-title":"From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection","volume":"20","author":"Volpedo","year":"2021","journal-title":"Expert Rev Vaccines."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3192960","DOI":"10.1155\/2021\/3192960","article-title":"FML\/QuilA-vaccinated dogs naturally infected with Leishmania infantum: serum cytokines, clinicopathological profile, and parasitological parameters","volume":"2021","author":"Almeida","year":"2021","journal-title":"Biomed Res Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3389\/fimmu.2018.01043","article-title":"Peptide vaccines for leishmaniasis","volume":"9","author":"De Brito","year":"2018","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1016\/S0264-410X(02)00302-X","article-title":"Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL\u00ae adjuvant","volume":"20","author":"Skeiky","year":"2002","journal-title":"Vaccine."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1016\/j.vaccine.2011.02.096","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis","volume":"29","author":"Chakravarty","year":"2011","journal-title":"Vaccine."},{"key":"B14","doi-asserted-by":"publisher","first-page":"104807","DOI":"10.1016\/j.micpath.2021.104807","article-title":"The immunity of the recombinant prokaryotic and eukaryotic subunit vaccines against cutaneous leishmaniasis","volume":"153","author":"Salari","year":"2021","journal-title":"Microb Pathog."},{"key":"B15","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1002\/jcp.30483","article-title":"Cognizance of posttranslational modifications in vaccines: a way to enhanced immunogenicity","volume":"236","author":"Ojha","year":"2021","journal-title":"J Cell Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.20944\/preprints202304.0903.v1","article-title":"Leishmaniasis: immune cells crosstalk in macrophage polarization","volume":"8","author":"Almeida","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5596876","article-title":"Macrophage polarization in the skin lesion caused by neotropical species of Leishmania sp","author":"Sandoval Pacheco","year":"","journal-title":"J Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"620144","DOI":"10.3389\/fimmu.2021.620144","article-title":"Unraveling the role of immune checkpoints in leishmaniasis","volume":"12","author":"de Freitas e Silva","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1016\/j.vaccine.2015.05.012","article-title":"Recent insights into cutaneous immunization: How to vaccinate via the skin","volume":"33","author":"Engelke","year":"2015","journal-title":"Vaccine."},{"key":"B20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.intimp.2019.02.008","article-title":"Host's immune response in unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis treated by meglumine antimoniate: a case-control study of Th1 and Th2 pathways","volume":"69","author":"Bamorovat","year":"2019","journal-title":"Int Immunopharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"773983","DOI":"10.3389\/fimmu.2021.773983","article-title":"Multifunctional, TNF-\u03b1 and IFN-\u03b3-secreting CD4 and CD8 T Cells and CD8High T cells are associated with the cure of human visceral leishmaniasis","volume":"12","author":"Rodrigues","year":"2021","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0265721","DOI":"10.1128\/mBio.02657-21","article-title":"Development and evaluation of a cryopreserved whole-parasite vaccine in a rodent model of blood-stage malaria","volume":"12","author":"Stanisic","year":"2021","journal-title":"MBio"},{"key":"B23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.22037\/nbm.v5i3.14942","article-title":"Current approaches to develop a live vaccine against leishmania","volume":"5","author":"Yeganeh","year":"2017","journal-title":"Nov Biomed"},{"key":"B24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3389\/fimmu.2014.00134","article-title":"Live vaccination tactics: possible approaches for controlling visceral leishmaniasis","volume":"5","author":"Saljoughian","year":"2014","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"107849","DOI":"10.1016\/j.exppara.2020.107849","article-title":"The potential of live attenuated vaccines against cutaneous leishmaniasis","volume":"210","author":"Zabala-Pe\u00f1afiel","year":"2020","journal-title":"Exp Parasitol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3390\/microorganisms11041043","article-title":"Next-generation leishmanization: revisiting molecular targets for selecting genetically engineered live-attenuated Leishmania","volume":"11","author":"Moreira","year":"2023","journal-title":"Microorganisms"},{"key":"B27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/icb.1984.14","article-title":"Vaccination against cutaneous Leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection","volume":"62","author":"Mitchell","year":"1984","journal-title":"Aust J Exp Biol Med Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.4049\/jimmunol.166.3.1921","article-title":"Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms","volume":"166","author":"Streit","year":"2001","journal-title":"J Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.actatropica.2010.04.007","article-title":"The influence of ecto-nucleotidases on Leishmania amazonensis infection and immune response in C57B\/6 mice","volume":"115","author":"de Souza","year":"2010","journal-title":"Acta Trop."},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0008-8749(85)90081-4","article-title":"Immunization of susceptible BALB\/c mice against Leishmania braziliensis","volume":"94","author":"Gorczynski","year":"1985","journal-title":"Cell Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-3024.1993.tb00587.x","article-title":"Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge","volume":"15","author":"Rivier","year":"1993","journal-title":"Parasite Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1128\/iai.61.12.5205-5213.1993","article-title":"An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB\/c mice against infection with virulent L. major","volume":"61","author":"Kimsey","year":"1993","journal-title":"Infect Immun"},{"key":"B33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1086\/374783","article-title":"Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines","volume":"187","author":"Daneshvar","year":"2003","journal-title":"J Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1371\/journal.pntd.0002757","article-title":"Gentamicin-attenuated Leishmania infantum vaccine: protection of dogs against canine visceral leishmaniosis in endemic area of Southeast of Iran","volume":"8","author":"Daneshvar","year":"2014","journal-title":"PLoS Negl Trop Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00005-008-0010-9","article-title":"Live attenuated Leishmania vaccines: a potential strategic alternative","volume":"56","author":"Silvestre","year":"2008","journal-title":"Arch Immunol Ther Exp."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-05088-4","article-title":"Whole genome sequencing of live attenuated Leishmania donovani parasites reveals novel biomarkers of attenuation and enables product characterization","volume":"7","author":"Gannavaram","year":"2017","journal-title":"Sci Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4049\/jimmunol.1800727","article-title":"Designer parasites: genetically engineered Plasmodium as vaccines to prevent malaria infection","volume":"202","author":"Goswami","year":"2019","journal-title":"J Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.pt.2016.09.012","article-title":"Time for genome editing: next-generation attenuated malaria parasites","volume":"33","author":"Singer","year":"2017","journal-title":"Trends Parasitol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fcimb.2017.00198","article-title":"Engineering of genetically arrested parasites (GAPs) for a precision malaria vaccine","volume":"7","author":"Kreutzfeld","year":"2017","journal-title":"Front Cell Infect Microbiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaz5629","article-title":"A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1","volume":"12","author":"Roestenberg","year":"2020","journal-title":"Sci Transl Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"106153","DOI":"10.1016\/j.actatropica.2021.106153","article-title":"Live attenuated Leishmania major p27 gene knockout as a novel vaccine candidate: a study on safety, protective immunity and efficacy against canine leishmaniasis caused by Leishmania infantum","volume":"225","author":"Elikaee","year":"2022","journal-title":"Acta Trop"},{"key":"B42","doi-asserted-by":"publisher","first-page":"10267","DOI":"10.1073\/pnas.92.22.10267","article-title":"Development of a safe live Leishmania vaccine line by gene replacement","volume":"92","author":"Titus","year":"1995","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1590\/S0074-02762002000700019","article-title":"Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease","volume":"97","author":"Amaral","year":"2002","journal-title":"Mem Inst Oswaldo Cruz."},{"key":"B44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0166-6851(01)00432-7","article-title":"Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor","volume":"120","author":"Joshi","year":"2002","journal-title":"Mol Biochem Parasitol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"9258","DOI":"10.1073\/pnas.160257897","article-title":"Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major","volume":"97","author":"Sp\u00e4th","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B46","doi-asserted-by":"publisher","first-page":"864031","DOI":"10.3389\/fimmu.2022.864031","article-title":"Sepahpour T. Leishmania major centrin gene- deleted parasites generate skin resident memory T-cell immune response analogous to leishmanization.","volume":"13","author":"Ismail","year":"2022"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18091865","article-title":"Monitoring and measuring autophagy","volume":"18","author":"Yoshii","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1038\/s41467-020-17154-z","article-title":"A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat Commun."},{"key":"B49","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1073\/pnas.93.12.6008","article-title":"Evidence from disruption of the Imcpb gene array of Leishmania mexicana that cysteine proteinases are virulence factors (protease\/parasite\/trypanosomatid\/transfection\/null mutant)","volume":"93","author":"Mottram","year":"1996","journal-title":"Cell Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"6794","DOI":"10.4049\/jimmunol.161.12.6794","article-title":"Leishmania mexicana cystein proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response","volume":"1810","author":"Alexander","year":"1998","journal-title":"J Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1016\/j.vaccine.2005.05.045","article-title":"Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models","volume":"24","author":"Saravia","year":"2006","journal-title":"Vaccine."},{"key":"B52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/mmi.14139","article-title":"Sterol methyltransferase is required for optimal mitochondrial function and virulence in Leishmania major","volume":"111","author":"Mukherjee","year":"2019","journal-title":"Mol Microbiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ijpara.2005.03.008","article-title":"Characterisation of a Leishmania mexicana knockout lacking guanosine diphosphate-mannose pyrophosphorylase","volume":"35","author":"Stewart","year":"2005","journal-title":"Int J Parasitol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.01057-20","article-title":"Leishmania encodes a bacterium-like 2,4-dienoyl-coenzyme a reductase that is required for fatty acid \u03b2-oxidation and intracellular parasite survival","volume":"11","author":"Semini","year":"2020","journal-title":"MBio."},{"key":"B55","doi-asserted-by":"publisher","first-page":"44708","DOI":"10.1074\/jbc.M308063200","article-title":"Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major","volume":"278","author":"Zufferey","year":"2003","journal-title":"J Biol Chem"},{"key":"B56","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1073\/pnas.0509196103","article-title":"Virulence of Leishmania major in macrophages and mice requires the gluconeogenic enzyme fructose-1,6-bisphosphatase","volume":"103","author":"Naderer","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1365-2958.2007.05730.x","article-title":"Molecular genetic analysis of purine nucleobase transport in Leishmania major","volume":"64","author":"Ortiz","year":"2007","journal-title":"Mol Microbiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13071-017-2198-1","article-title":"Leishmania LABCG1 and LABCG2 transporters are involved in virulence and oxidative stress: functional linkage with autophagy","volume":"10","author":"Manzano","year":"2017","journal-title":"Parasit Vectors."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1005340","article-title":"A trypanosomatid iron transporter that regulates mitochondrial function is required for Leishmania amazonensis virulence","volume":"12","author":"Mittra","year":"2016","journal-title":"PLoS Pathog."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00349-18","article-title":"Glucose transporters and virulence in Leishmania mexicana","author":"Feng","year":"2018","journal-title":"mSphere"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0134432","article-title":"Kharon1 null mutants of leishmania mexicana are avirulent in mice and exhibit a cytokinesis defect within macrophages","volume":"10","author":"Tran","year":"2015","journal-title":"PLoS ONE."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-07412-z","article-title":"Absence of DEATH kinesin is fatal for Leishmania mexicana amastigotes","volume":"12","author":"Al Kufi","year":"2022","journal-title":"Sci Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/mmi.12383","article-title":"The Leishmania major BB some subunit BBS1 is essential for parasite virulence in the mammalian host","volume":"90","author":"Price","year":"2013","journal-title":"Mol Microbiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"11965","DOI":"10.1073\/pnas.1004599107","article-title":"Expansion of the target of rapamycin (TOR) kinase family and function in Leishmania shows that TOR3 is required for acidocalcisome biogenesis and animal infectivity","volume":"107","author":"Madeira Da Silva","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e0052612","DOI":"10.1371\/journal.pone.0052612","article-title":"Novel features of a PIWI-like protein homolog in the parasitic protozoan Leishmania","volume":"7","author":"Padmanabhan","year":"2012","journal-title":"PLoS ONE"},{"key":"B66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.exppara.2010.04.009","article-title":"Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity.","volume":"126","author":"Taheri","year":"2010","journal-title":"Exp Parasitol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00449-1","article-title":"Centrin-deficient Leishmania mexicana confers protection against new world cutaneous leishmaniasis","volume":"7","author":"Volpedo","year":"2022","journal-title":"NPJ Vaccines."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00625-19","article-title":"LeishIF4E1 deletion affects the promastigote proteome, morphology, and infectivity","author":"Tupperwar","year":"2019","journal-title":"mSphere"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1009666","article-title":"The kinesin of the flagellum attachment zone in Leishmania is required for cell morphogenesis, cell division and virulence in the mammalian host","volume":"17","author":"Corrales","year":"2021","journal-title":"PLoS Pathog."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0192723","article-title":"CRISPR\/Cas9 in Leishmania mexicana: a case study of LmxBTN1","volume":"13","author":"Ishemgulova","year":"2018","journal-title":"PLoS One."},{"key":"B71","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/mmi.13375","article-title":"Conditional gene deletion with DiCre demonstrates an essential role for CRK3 in Leishmania mexicana cell cycle regulation","volume":"100","author":"Duncan","year":"2016","journal-title":"Mol Microbiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.molbiopara.2017.06.005","article-title":"Recent advances in Leishmania reverse genetics: manipulating a manipulative parasite","volume":"216","author":"Duncan","year":"2017","journal-title":"Mol Biochem Parasitol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/mmi.13374","article-title":"Joining forces: first application of a rapamycin-induced dimerizable Cre system for conditional null mutant analysis in Leishmania","volume":"100","author":"Sp\u00e4th","year":"2016","journal-title":"Mol Microbiol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","article-title":"The next generation of CRISPR\u2013Cas technologies and applications","volume":"20","author":"Pickar-Oliver","year":"2019","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.aat5011","article-title":"Doudna JA. CRISPR-Cas guides the futurepdf","volume":"361","author":"Knott","year":"2018","journal-title":"Science."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e00861","DOI":"10.1128\/mBio.00861-15","article-title":"CRISPR-Cas9-mediated genome editing in Leishmania donovani","volume":"6","author":"Zhang","year":"2015","journal-title":"MBio"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0339-7","article-title":"Recent advances in the CRISPR genome editing tool set","volume":"51","author":"Moon S","year":"2019","journal-title":"Exp Mol Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/jipb.12152","article-title":"Self-processing of ribozyme-flanked RNAs into guide RNAs in vitro and in vivo for CRISPR-mediated genome editing","volume":"56","author":"Gao","year":"2014","journal-title":"J Integr Plant Biol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e1010375","DOI":"10.1371\/journal.ppat.1010375","article-title":"Experimental evolution links posttranscriptional regulation to Leishmania fitness gain","volume":"18","author":"Piel","year":"2022","journal-title":"PLoS Pathog"},{"key":"B81","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.pt.2020.06.005","article-title":"Gene editing in trypanosomatids: tips and tricks in the CRISPR-Cas9 era","volume":"36","author":"Yagoubat","year":"2020","journal-title":"Trends Parasitol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"104733","DOI":"10.1016\/j.micpath.2021.104733","article-title":"Adjuvanted vaccines driven protection against visceral infection in BALB\/c mice by Leishmania donovani","volume":"151","author":"Goyal","year":"2021","journal-title":"Microb Pathog"},{"key":"B83","doi-asserted-by":"publisher","first-page":"8677","DOI":"10.3390\/molecules27248677","article-title":"Polylactide nanoparticles as a biodegradable vaccine adjuvant: a study on safety, protective immunity and efficacy against human leishmaniasis caused by Leishmania major","volume":"27","author":"Ayari-Riabi","year":"2022","journal-title":"Molecules"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a038059","article-title":"Long-lived skin-resident memory T cells contribute to concomitant immunity in cutaneous leishmaniasis","volume":"12","author":"Scott","year":"2020","journal-title":"Cold Spring Harb Perspect Biol."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1382996\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T05:14:16Z","timestamp":1720156456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1382996\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":84,"alternative-id":["10.3389\/fpubh.2024.1382996"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1382996","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"article-number":"1382996"}}